SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-005144
Filing Date
2023-01-20
Accepted
2023-01-20 06:00:32
Documents
17
Period of Report
2023-01-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm233842d1_8k.htm   iXBRL 8-K 36516
2 EXHIBIT 10.1 tm233842d1_ex10-1.htm EX-10.1 50424
3 EXHIBIT 10.2 tm233842d1_ex10-2.htm EX-10.2 48285
4 EXHIBIT 10.3 tm233842d1_ex10-3.htm EX-10.3 59624
5 EXHIBIT 10.4 tm233842d1_ex10-4.htm EX-10.4 59589
6 GRAPHIC tm233842d1_ex10-3img001.jpg GRAPHIC 3988
  Complete submission text file 0001104659-23-005144.txt   500633

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20230115.xsd EX-101.SCH 3030
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20230115_lab.xml EX-101.LAB 34476
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20230115_pre.xml EX-101.PRE 22593
11 EXTRACTED XBRL INSTANCE DOCUMENT tm233842d1_8k_htm.xml XML 3775
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 23538807
SIC: 2834 Pharmaceutical Preparations